Novaral reached its target in a late-stage QMF149 asthma trial

novart announced that its Phase III QUERTZ study on its research-based inhalation joint treatment QMF149 has met the primary and critical secondary endpoints for patients with poor asthma control. Daily fixed-dose treatment showed significant improvements in lung function and asthma control compared to inhalation of corticosteroids (ICS) alone.The results of the first study showed a statistically significant improvement in lung function in the combination of acetic aciddatero and mormisson, which was measured by 'FEV', which is the amount of air that can be squeezed out within a second of deep breathing - about 24 hours after the last time the study drug was taken.the study included 802 male and female patients with an average age of 45.6 years and an average asthma duration of 14 years.Novarian is very pleased with quARTZ's findings, which examine the efficacy and safety of the fixed dose combination of datro and momisson, acetic acid," commented Dr. Oliver Kornmann of the Department of Lung Medicine, Department of Internal Medicine, Mainz University Hospital, Germany.The fixed-dose combination inhalers can provide an advantage for asthma sufferers by simplifying complex inhalation treatment options, especially when they are given once a day, further reducing the burden of the disease," he continued.affects about 358 million people worldwide and, if not adequately controlled, can cause serious personal, health and financial burdens, but despite extensive asthma treatment, more than a third of patients remain out of control."Despite the variety of treatments available, many patients' lives are still affected by asthma," said Linda Armstrong, head of respiratory development. She continued, "The QMF149 results of the QUARTZ study supplement the QVM149 Phase II data recently presented at the 2019 American Thoracic Technology Association Conference and show that QVM149 is superior to current standards of care. We look forward to seeing additional data from the PLATINUM Clinical Trial Program. "This combination is currently being developed to treat asthma in patients who still have symptoms despite the current treatment. (Compiled by this web)